Acoramidis
Amyloid Cardiomyopathy, Transthyretin-Related
Eidos Therapeutics, a BridgeBio companySmall moleculePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Amyloid Cardiomyopathy, Transthyretin-Related cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
TECHNETIUM TC 99M PYROPHOSPHATE Mathew S. Maurer, MD | D | |
Technetium Tc-99m Oxidronate Mathew S. Maurer, MD | D |
Same molecule, other indications
Acoramidis is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →